Evidence map›Paper›PMID 40824894›Full record

ArticlePloS one2025

Deep learning-based Alzheimer's disease detection using magnetic resonance imaging and gene expression data.

Badar Almarri

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Badar AlmarriDepartment of Computer Science, College of Computer Science and Information Technology, King Faisal University, Al Ahsa, Saudi Arabia.ORCID https://orcid.org/0000-0002-0960-3727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) poses significant challenges to healthcare systems across the globe. Early and accurate AD diagnosis is crucial for effective management and treatment. Recent advances in neuroimaging and genomics provide an opportunity for developing multi-modality-based AD diagnosis models using artificial intelligence (AI) techniques. However, the data complexities cause challenges in developing interpretable AI-based AD identification models. In this study, the author built a comprehensive AD diagnostic model using magnetic resonance imaging (MRI) and gene expression data. MobileNet V3 and EfficientNet B7 model was employed to extract AD features from gene expression data. The author introduced a hybrid TWIN-Performer-based feature extraction model to derive features from MRI. The attention-based feature fusion was used to fuse the crucial features. An ensemble learning-based classification model integrating CatBoost, XGBoost, and extremely randomized tree (ERT) was developed to identify cognitively normal (CN) and AD features. The proposed model was validated on diverse datasets. It achieved a superior performance on MRI and gene expression datasets. The area under the receiver operating characteristic (AUROC) scores were consistently above 0.85, indicating excellent model performance. The use of Shapley Additive exPlanations (SHAP) values improved the model's interpretability, leading to earlier interventions and personalized treatment strategies.

Indexed as

Alzheimer DiseaseDeep LearningMagnetic Resonance ImagingGene Expression ProfilingHumansMaleROC Curve

Identifiers

PMID40824894
PMCPMC12440570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.